Patents by Inventor David Michael Hone

David Michael Hone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant BCG strains with enhanced ability to escape the endosome
    Patent number: 8043857
    Abstract: Mycobacterium strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express: a endosomalytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of the cell; and antigens of interest, such as tuberculosis antigens. The invention also provides vaccine preparations containing such Mycobacterium strains.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: October 25, 2011
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Electroporation of and overexpression of antigens in mycobacteria
    Patent number: 7829104
    Abstract: Recombinant Mycobacterium strains with improved vaccinal properties for use as vaccinating agents are provided. The parent strains of the recombinant Mycobacterium strains are selected for their potent immunogenicity. The Mycobacterium strains do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: November 9, 2010
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Recombinant BCG Strains with Enhanced Ability to Escape the Endosome
    Publication number: 20100233213
    Abstract: Mycobacterium strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express: a endosomalytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of the cell; and antigens of interest, such as tuberculosis antigens. The invention also provides vaccine preparations containing such Mycobacterium strains.
    Type: Application
    Filed: December 31, 2009
    Publication date: September 16, 2010
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Recombinant BCG strains with enhanced ability to escape the endosome
    Patent number: 7666656
    Abstract: Mycobacterium strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8+ T cell immune response are provided. The Mycobacterium strains are genetically engineered to express: a endosomolytic protein that is active at neutral pH (e.g. Perfringolysin O), permitting escape of the Mycobacterium from endosomes into the cytoplasm of the cell; and antigens of interest, such as tuberculosis antigens. The invention also provides vaccine preparations containing such Mycobacterium strains.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: February 23, 2010
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Transformed bacterium lacking selectable marker and overexpression of antigens in mycobacteria
    Patent number: 7625572
    Abstract: Recombinant Mycobacterium strains with improved vaccinal properties for use as vaccinating agents are provided. The parent strains of the recombinant Mycobacterium strains are selected for their potent immunogenicity. The Mycobacterium strains do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: December 1, 2009
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Webbed immunogens comprising recombinant human immunodeficiency virus (HIV) envelope glycoproteins and the M9 scorpion toxin
    Patent number: 7537769
    Abstract: HIV envelope immunogens that display multivalent epitopes are provided. The immunogens are aggregated, “webbed” HIV envelope immunogens in which native envelope structures are stabilized due to interactions with multimeric derivatives of M9 scorpion toxin.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: May 26, 2009
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: David Michael Hone, David Yetu Onyabe
  • Electroporation of Mycobacterium and Overexpression of Antigens in Mycobacteria
    Publication number: 20080286852
    Abstract: Recombinant Mycobacterium strains with improved vaccinal properties for use as vaccinating agents are provided. The parent strains of the recombinant Mycobacterium strains are selected for their potent immunogenicity. The Mycobacterium strains do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria.
    Type: Application
    Filed: May 31, 2007
    Publication date: November 20, 2008
    Inventors: Ronggai Sun, David Michael Hone, Jerald C. Sadoff
  • Recombinant double-stranded RNA phage, and use of the same
    Patent number: 7018835
    Abstract: A recombinant double stranded RNA (dsRNA) phage expresses dsRNA-encoded genes in eukaryote cells. Recombinant dsRNA phage are useful for the expression of dsRNA expression cassettes encoding passenger genes, such as, but not restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Methods are provided to deliver recombinant dsRNA phage to eukaryotic cells and tissues, either by direct administration, formulated in lipid or polylactide-coglycolide, or by utilizing a bacterial vaccine vector.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: March 28, 2006
    Inventor: David Michael Hone